{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T10:41:40Z","timestamp":1697107300090},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,10,15]],"date-time":"2003-10-15T00:00:00Z","timestamp":1066176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2003,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glycoprotein IIb\/IIIa receptor antagonists, such as abciximab, are used to reduce major adverse cardiac events (MACEs) in patients undergoing percutaneous transluminal coronary angioplasty. The goal of this study was to evaluate the administration of abciximab in relation to lesion complexity and periprocedural complications. A total of 357 patients with 435 de novo lesions were included in this study. Lesions were divided into simple (type A and type B1) and complex (type B2 and type C) lesions according to the American College of Cardiology\/American Heart Association Task Force lesion complexity system. Abciximab was given to unstable complex lesions and simple lesions with a periprocedural unstable complicated course. The overall incidence of MACE during the 9\u2010month follow\u2010up period was 17.0%. Patients treated with abciximab had a higher lesion complexity (<jats:italic>P<\/jats:italic> &lt; 0.001), dissections (<jats:italic>P<\/jats:italic> = 0.014), stents (<jats:italic>P<\/jats:italic> &lt; 0.001), and vessels involved (<jats:italic>P<\/jats:italic> &lt; 0.001). in addition, the abciximab group was characterized by a higher angina NYHA class (<jats:italic>P<\/jats:italic> = 0.005), lower TIMI flow prior to stenting (<jats:italic>P<\/jats:italic> = 0.01), and a longer total inflation time (<jats:italic>P<\/jats:italic> = 0.006). Despite these clinical differences, the occurrence of MACE within the abciximab group was slightly less than in the group without abciximab (16.2% and 17.3%, respectively). Lesion complexity was directly related to MACE in the group that did not receive abciximab (simple and stable complex lesions; <jats:italic>P<\/jats:italic> = 0.04). On the other hand, in subjects treated with abciximab, lesion complexity was not related to a higher incidence of MACE (<jats:italic>P<\/jats:italic> = 0.76). The use of abciximab equalizes the difference in outcome between simple and complex lesions. Therefore, abciximab should be advocated especially in unstable and complex percutaneous coronary interventions. Catheter Cardiovasc Interv 2003;60:339\u2013343. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.10654","type":"journal-article","created":{"date-parts":[[2003,10,17]],"date-time":"2003-10-17T12:02:52Z","timestamp":1066392172000},"page":"339-343","source":"Crossref","is-referenced-by-count":4,"title":["Clinical impact of abciximab on long\u2010term outcome after complex coronary angioplasty"],"prefix":"10.1002","volume":"60","author":[{"given":"Jasper S.","family":"Wijpkema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian A.J.","family":"Jessurun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad J.","family":"Van Boven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dik I.K.","family":"Versteeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond W.M.","family":"Hautvast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 A.","family":"Tio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.78.2.486"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.19.1971"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.4.1193"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"e_1_2_5_7_2","first-page":"79","article-title":"Acute platelet inhibition with abciximab does not reduce in\u2010stent restenosis (ERASER study)","volume":"100","author":"ERASER investigators","year":"1999","journal-title":"Circulation"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo\u2010controlled and balloon\u2010angioplasty\u2010controlled trial to assess safety of coronary stenting with use of platelet glycoprotein\u2010IIb\/IIIa blockade","volume":"352","author":"EPISTENT investigators","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013404"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.8.734"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00635-X"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442503"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.1810280301"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01290-6"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.12.1285"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441502"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.10654","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.10654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T09:12:44Z","timestamp":1697015564000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.10654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,15]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["10.1002\/ccd.10654"],"URL":"https:\/\/doi.org\/10.1002\/ccd.10654","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,15]]}}}